StemCells Therapy » Stem Cells

International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology’s Brand of Human Cell Culture…

admin — Thu, 29 Jul 2010 08:21:20 +0000

International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com, via its wholly-owned subsidiary, Lifeline Cell Technology® (Lifeline) www.lifelinecelltech.com, and Sristi Biosciences, www.sristibio.com, have entered into a distribution agreement for the Lifeline® brand of human cell culture products in India.

Lifeline specializes in development, manufacture and distribution of primary human cells and media and growth factors for optimized culturing of cells, including stem cells. These products are being requested by customers internationally, including in India, which represents one of the fastest growing markets for products of this kind.

According to Lifeline’s CEO and SVP of Operations at ISCO, Jeffrey Janus, ‘Sristi Biosciences is part of one of the most experienced biotechnology companies in India and the first to advance cell therapy into human trials in that country. Their network among academic and corporate researchers and experience and capacity to import and handle primary cell cultures, media and growth factors in India will be highly valuable for Lifeline to continue the international commercial expansion of its brand.’

Lifeline’s scientists have over 20 years of experience developing products for the culture of human cells. The company has made significant contributions to the creation and standardization of human cell systems used today for clinical applications and in academic, government and pharmaceutical research laboratories. The group sells over 75 standardized products directly and via its distributors in the US and abroad. It also engages in customized product development for its largest customers.

Dr. Sudhir Reddy, Sristi Biosciences’ CEO adds, ‘We are pleased to be the first company to introduce the Lifeline products to the growing Indian research market. Our cell culture experience and broad market reach in India will benefit the brand and help Sristi Biosciences further accelerate its commercialization and corporate growth in the biomedical field.’

ISCO recently announced the beginning of a collaboration on its human corneal tissue, CytoCor™, with leading Indian eye hospital and research center, Sankara Nethralaya, and Letter of Intent with Insight Bioventures India (IBVI) to seek funding and establishment of development and manufacturing operations for ISCO’s research and pharmaceutical products in India (ISCO India), including the Lifeline products and CytoCor.

‘The Lifeline distribution agreement with Sristi Biosciences is central to ISCO’s international expansion. Besides facilitating commercialization of the Lifeline products in India, Sristi Biosciences’ cell therapy development, regulatory and manufacturing expertise will be important as ISCO and IBVI seek to establish ISCO India with cost-efficient development and manufacturing of research and pharmaceutical products for the Indian and broader Asian markets,’ says Brian Lundstrom, ISCO’s President.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO’s core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and is developing a line of cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO’s website.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

ABOUT SRISTI BIOSCIENCES

Sristi Biosciences Private Limited is a result of twelve years of research and corporate development in the therapeutic space and is the healthcare component of leading biotechnology group, SRI Biotech, in India. Sristi Biosciences’ two main divisions include Tissue Engineering and Cell Therapy that has pioneered chondrocytes-based cell therapy in India and Drug Discoverythat covers the Indian research product market with natural compound libraries, molecular diagnostics and markers, informatics and cell-based products. Sristi’s integrated research and development facility in Hyderabad is state-of-the-art and the company has wide collaborative and commercial presence across the research market in India, including 23 leading biotech institutes and major corporate bodies.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments and therapeutic applications, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
Or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com

Ivy Bean, online phenomenon considered world’s oldest Twitter user, dies at 104

admin — Thu, 29 Jul 2010 08:21:03 +0000

‘World’s oldest tweeter’ Ivy Bean dies at 104

LONDON — Ivy Bean, who became an online celebrity as the oldest known user of micro-blogging site Twitter, has died at the age of 104.
Pat Wright, manager of the care home where she lived in Bradford, northern England, says Bean died peacefully early Wednesday.
Wright said Bean “grabbed new …. Original source : Ivy Bean, online phenomenon considered world’s oldest Twitter user, dies at 104.

Growth in search, Match contributes to IAC second-quarter revenue increase, but profit down

admin — Thu, 29 Jul 2010 08:21:03 +0000

Growth in search, Match contributes to IAC revenue

SAN FRANCISCO — IAC/InterActiveCorp reported stronger second-quarter revenue Wednesday, citing growth in its search and Match online dating businesses. Net income fell, however, because the comparison quarter a year ago included a bump from the sale of its Match Europe operations.
IAC’s core search businesses, which include the search … Read : Growth in search, Match contributes to IAC second-quarter revenue increase, but profit down.

What’s in your phone app? More than you’d like it to know, new research shows

admin — Thu, 29 Jul 2010 08:21:03 +0000

more images

What your phone app doesn’t say: It’s watching
LAS VEGAS — Your smart phone applications are watching you — much more closely than you might like.
Lookout Inc., a mobile-phone security firm, scanned nearly 300,000 free applications for Apple Inc.’s iPhone and phones built around Google Inc.’s Android software. It found that many of …. Read the original article : here.

At a glance, how tech industry earnings have reflected a rebound in spending

admin — Thu, 29 Jul 2010 08:21:02 +0000

more images

A look at recent tech-industry earnings
Here is a summary of recent earnings reports for selected technology companies and what they reveal about the state of spending and the overall economy:
July 13: Intel Corp. reports its largest quarterly net income in a decade as the chipmaker benefits from a stronger computer market and more … Read the original article on Gaea Times at : At a glance, how tech industry earnings have reflected a rebound in spending.

Google’s New Bid to Take on Facebook

admin — Thu, 29 Jul 2010 08:21:02 +0000

more images

After a number of failing attempts to extend its monopoly over online social networking, search engine major Google was reported to be working on a new social networking project to challenge Facebook’s domination in the field. Starting with their no-so-successful venture into social networking – Orkut, Google’s launched an array of social networking products … Read the original article on Gaea Times at : Google’s New Bid to Take on Facebook.

Mouse Fat Cells ‘Reprogram’ Into Clinically Useful Stem Cells

admin — Thu, 29 Jul 2010 08:20:59 +0000

Australian scientists from the Monash Institute of Medical Research have “reprogrammed” adult mouse fat cells and neural cells to become stem cells that can differentiate into a variety of different cells (pluripotency). The cells, called “induced pluripotent stem cells” (iPS), are nearly identical to the naturally occurring pluripotent stems cells, such as embryonic stem cells, which are highly …

International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology’s Brand of Human Cell Culture…

admin — Thu, 29 Jul 2010 08:20:57 +0000

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

ABOUT SRISTI BIOSCIENCES

FORWARD-LOOKING STATEMENTS

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
Or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com

International Stem Cell Corporation and Sristi Biosciences Enter into Distribution Agreement for Lifeline Cell …

admin — Thu, 29 Jul 2010 08:20:55 +0000

OCEANSIDE, Calif. & HYDERABAD, India—-International Stem Cell Corporation , www.internationalstemcell.com, via its wholly-owned subsidiary, Lifeline Cell Technology® www.lifelinecelltech.com, and Sristi Biosciences, www.sristibio.com, have entered into a distribution agreement for the Lifeline® brand of human cell …

Scientists identify new targets to develop treatment for HD

admin — Thu, 29 Jul 2010 08:20:54 +0000

Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington’s disease. These enzymes, matrix metalloproteinases, provide new targets for drug therapies for the disease – targets that have already been shown to respond to cancer drugs currently in clinical development.

Managing More than 300 Grants: CIRM’s Thin Ice Question

admin — Thu, 29 Jul 2010 08:20:52 +0000

A key panel of directors of the California stem cell agency on Tuesday will wrestle with ongoing issues involving its critical grants management system and consider changes in its policies concerning the many outside contractors CIRM is forced to rely on.

The agency has already posted some background information for the Governance Subcommittee meeting including a list of current contracts and

Stem cells coaxed to rebuild bone

admin — Thu, 29 Jul 2010 08:18:09 +0000

In a world first, scientists have coaxed stem cells in live rabbits to rebuild the bone and cartilage of a missing leg joint, according to a new study.

Toshiba returns to the black in April-June quarter on brisk global demand for memory chips

admin — Thu, 29 Jul 2010 08:07:13 +0000

Toshiba returns to the black in April-June quarter

TOKYO — Toshiba Corp. returned to the black last quarter thanks to a recovery in global demand for flash memory chips used in smartphones and digital cameras.
The Japanese conglomerate — whose vast business ranges from household appliances to nuclear power systems — said Thursday its net profit was … Read this article on Gaea Times at : Toshiba returns to the black in April-June quarter on brisk global demand for memory chips.

Scientists develop new surgical procedure for prostate cancer using natural orifices

admin — Thu, 29 Jul 2010 08:05:19 +0000

With a recent first of its kind surgery, physicians at Mayo Clinic in Arizona have developed a new surgical procedure for the treatment of prostate cancer using natural orifices – signaling the next step in the evolution of minimally invasive surgery.

Genetic signals determines neurotransmitter for communicating with other cells

admin — Thu, 29 Jul 2010 07:59:26 +0000

Cascades of genetic signals determine which neurotransmitter a brain cell will ultimately use to communicate with other cells. Now a pair of reports from biologists at the University of California, San Diego, have shown for the first time that electrical activity in these developing neurons can alter their chemical fate-and change an animal’s behavior-by tweaking this genetic program.

Quarterly profit for Taiwan chipmaker TSMC climbs 65 percent on strong wafer demand

admin — Thu, 29 Jul 2010 07:59:11 +0000

Taiwan chipmaker TSMC says profit up 65 percent

TAIPEI, Taiwan — Taiwan Semiconductor Manufacturing Co., the world’s largest contract chipmaker, said its second quarter profit jumped 65 percent year-on-year amid strong worldwide demand for electronic goods.
Net profit for the April-June period was a record 40.3 billion New Taiwan dollars ($1.3 billion) on consolidated revenue of NT$105 …. Read the original article : here.

France Telecom reports first half increase in net profit on one-off gain

admin — Thu, 29 Jul 2010 07:56:04 +0000

France Telecom first half net profit up 45 pct

PARIS — France Telecom SA said Thursday that first half net profit rose 45 percent due to a one-off gain, although revenue and margins were eroded by regulatory costs and competition in the home market in France.
Net profit in the six months to the end of June … Read more >>.

Study shows high rate of atrial fibrillation in patients with early stages of CKD

admin — Thu, 29 Jul 2010 07:51:25 +0000

Millions of Americans in the early stages of chronic kidney disease (CKD) are at an increased risk of having atrial fibrillation (AF) – a major risk factor for stroke – according to new research by investigators at Wake Forest University Baptist Medical Center.

Panasonic plans to buy out subsidiaries Sanyo, Panasonic Electric under $9.4B green initiative

admin — Thu, 29 Jul 2010 07:48:40 +0000

more images

Panasonic buying out Sanyo, Panasonic Electric
TOKYO — Panasonic is planning to take 100 percent ownership of its subsidiaries Sanyo Electric and Panasonic Electric Works in a move costing up to $9.4 billion to strengthen green businesses such as electric cars and solar panels.
Panasonic Corp., Japan’s biggest consumer electronics maker, said in a statement … Original source on Gaea Times at : Panasonic plans to buy out subsidiaries Sanyo, Panasonic Electric under $9.4B green initiative.

Mayo leaps into social media marketing

admin — Thu, 29 Jul 2010 07:40:38 +0000

The Mayo Clinic is opening a school of social media for health providers, the (Minneapolis-St. Paul) Star Tribune reports. The new “Center for Social Media… [will] train other health care organizations to use Twitter, YouTube and Facebook to connect patients and doctors.